AstraZeneca Looks To Block Generic Pulmicort

Law360, New York (August 14, 2012, 2:59 PM EDT) -- AstraZeneca PLC on Monday asked a New Jersey federal court to block the manufacture and distribution of a generic version of its Pulmicort Respules asthma medication for children by Breath Ltd.

AstraZeneca is seeking a preliminary injunction against Breath’s proposed generic, which AstraZeneca says is described in Breath’s abbreviated new drug application as the bioequivalent to Pulmicort, with the same active ingredient and the same proposed labeling.

London-based AstraZeneca disputes Breath's claim that its patents for the drug are invalid, unenforceable or not infringed, the complaint...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.